The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeal's court.

The other three — Tofidence™ and Tyenne® for Actemra® (tocilizumab) and Pavblu™ for Eylea® (aflibercept) — were the first commercially available biosimilars for their respective ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung Huynh tells investors in “negative, but ...

Alvotech is currently developing AVT29, a biosimilar candidate for EYLEA® HD 8 mg. Teva holds commercialization rights for AVT29 in the United States. As we have previously reported, Alvotech and ...

BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in its Eylea biosimilar case “comes as expected by ...

About Eydenzelt ® (CT-P42, biosimilar aflibercept) Eydenzelt ® (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor referencing Eylea ®. Based on comprehensive data from a ...

The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise. The medicine's sales growth has slowed ...

The US Food and Drug Administration (FDA) approved Sandoz’s Enzeevu (aflibercept-abzv), the drugmaker’s biosimilar for wet age-related macular degeneration (AMD), in August 2024. Despite ...

so as such this news is a non-event - as recent stock downside looked to have already more than fully baked in Eylea sales erosion from biosimilars and Vabysmo competition," Abrahams wrote.